Effects of secondary prophylaxis started in adolescent and adult haemophiliacs

Summary.  While primary prophylaxis is a well‐established and recommended method of care delivery for children with severe haemophilia, fewer studies have documented the benefits of secondary prophylaxis started in adolescence or adulthood. To evaluate the role of secondary prophylaxis started in adolescent and adult severe haemophiliacs, a retrospective observational cohort study was conducted in 10 Italian Centres that investigated 84 haemophiliacs who had bled frequently and had thus switched from on‐demand to prophylactic treatment during adolescence (n = 30) or adulthood (n = 54). The consumption of clotting factor concentrates, the orthopaedic and radiological scores, quality of life and disease‐related morbidity were compared before and after starting secondary prophylaxis. Prophylaxis reduced the mean annual number of total and joint bleeds (35.8 vs. 4.2 and 32.4 vs. 3.3; P < 0.01) and of days lost from work/school (34.6 vs. 3.0, P < 0.01). A statistically significant reduction in the orthopaedic score was observed during prophylaxis in adolescents, but not in the whole cohort. Patients used more factor concentrates with corresponding higher costs on prophylaxis, but experienced a better quality of life. With respect to on‐demand treatment, higher factor consumption and cost of secondary prophylaxis were balanced by marked clinical benefits and greater well‐being in this cohort of adolescent/adult haemophiliacs.

[1]  L. Mantovani,et al.  Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  C. Hermans,et al.  Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  F. Lafeber,et al.  Prophylactic treatment for prevention of joint disease in hemophilia--cost versus benefit. , 2007, The New England journal of medicine.

[4]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[5]  C. Hay Prophylaxis in adults with haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  M. Franchini,et al.  Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs , 2006, Thrombosis and Haemostasis.

[7]  A. Iorio,et al.  Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. , 2006, The Cochrane database of systematic reviews.

[8]  K. Fischer,et al.  Can long‐term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands , 2005, British journal of haematology.

[9]  R. Ljung,et al.  Changing pattern of care of boys with haemophilia in western European centres , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  E. Remor,et al.  Disease‐specific quality‐of‐life measurement tools for haemophilia patients , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  L. Valentino Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  V. Blanchette,et al.  Development of a health‐related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes – Kids Life Assessment Tool (CHO‐KLAT) , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  K. Fischer,et al.  Health‐related quality of life as outcome parameter in haemophilia treatment , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  D. Grobbee,et al.  Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  A. Miners,et al.  Experience of prophylaxis treatment in children with severe haemophilia , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  P. Giangrande,et al.  Clinical outcomes and resource utilization associated with haemophilia care in Europe , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  F. Beek,et al.  Long‐term outcome of individualized prophylactic treatment of children with severe haemophilia , 2001, British journal of haematology.

[18]  Mannucci,et al.  Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  C. Sabin,et al.  Assessing the effectiveness and cost‐effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease , 1998, Journal of internal medicine.

[20]  J. Avorn,et al.  Prophylactic Use of Factor VIII: an Economic Evaluation , 1998, Thrombosis and Haemostasis.

[21]  J. Goldman,et al.  Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion , 1997, Transfusion.

[22]  H. Pettersson,et al.  Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.

[23]  S. Böttger,et al.  Radiological score in paediatric haemophilic patients with early and late onset of factor VIII-prophylaxis. , 1996, Thrombosis and haemostasis.

[24]  K. Khair,et al.  The impact of prophylactic treatment on children with severe haemophilia , 1996, British journal of haematology.

[25]  P. Mannucci,et al.  Modern treatment of haemophilia. , 1995, Bulletin of the World Health Organization.

[26]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[27]  M. Gilbert Prophylaxis: musculoskeletal evaluation. , 1993, Seminars in hematology.

[28]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[29]  J. Oldenburg,et al.  Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. , 1992, Haemostasis.

[30]  H. Pettersson,et al.  A radiologic classification of hemophilic arthropathy. , 1980, Clinical orthopaedics and related research.